Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company's lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, as well as to treat brain cancers and/or certain neurodegenerative diseases; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and cell therapy products for bone marrow/hematopoietic stem cell transplantation. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.
0.0031 | |
0.0031 | |
- | |
0.0031 | |
0.0031 | |
0.0031-0.2 | |
23 367 K | |
1 342 M | |
0 | |
-0.0046 | |
3.144 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: